NEUROPATHIC OCULAR PAIN MARKET ANALYSIS

Neuropathic Ocular Pain Market, By Drug Class (Steroids, Non-Steroidal Anti-Inflammatory Drugs, Antidepressants, Anticonvulsants, Opioids, and Others (Vitamin B supplements, Botulinum toxin A, and others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2023
Code : CMI5600
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Side effects associated with ocular pain management drugs

Global Neuropathic Ocular Pain Market- Driver

Rise in awareness of the importance of eye health

An increase in awareness campaigns regarding the importance of eye health is expected to drive the market growth over the forecast period. For instance, in June 2021, the National Alliance for Eye and Vision Research (NAEVR), in collaboration with Tear Film & Ocular Surface Society Boston, a U.S.-based organization involved in educating people relating to eye health, announced that they hosted a dry eye awareness campaign in the U.S. to educate people regarding the importance of eye health.

An increase in collaboration and partnership by key market players

Key market players are adopting growth strategies such as partnerships and collaborations to launch new products. This is expected to drive the market growth over the forecast period. For instance, in October 2020, Ocular Therapeutix, Inc., a biopharmaceutical company, announced that it had collaborated with AffaMed Therapeutics, a clinical-stage biopharmaceutical company, to launch DEXTENZA, a U.S. FDA-approved product for the management of ocular pain, in Greater China, South Korea, and the ASEAN markets.

Figure 2. Global Neuropathic Ocular Pain Market Share (%), by Region, 2023